Use of Impella Devices for Acute Cardiogenic Shock in the Perioperative Period of Cardiac Surgery

被引:1
|
作者
Sicouri, Serge [1 ]
Shah, Vishal N. [2 ]
Buckley, Meghan [1 ]
Imperato, Nicholas [1 ]
McGee, Jacqueline [3 ]
Casanova, Elena
Gnall, Eric
Plestis, Konstadinos A. [3 ]
机构
[1] Lankenau Inst Med Res, Wynnewood, PA 19096 USA
[2] Thomas Jefferson Univ Hosp, Dept Cardiothorac Surg, Philadelphia, PA 19107 USA
[3] Lankenau Med Ctr, Div Cardiol, Wynnewood, PA USA
关键词
Extracorporeal Membrane Oxygenation; Shock; Cardiogenic; Heart Ventricles; Aortic Valve; Hemodynamics; Cardiac Surgical procedures; Perioperative Period; MECHANICAL CIRCULATORY SUPPORT; EARLY INITIATION; SURVIVAL;
D O I
10.21470/1678-9741-2021-0398
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The Impella ventricular support system is a device that can be inserted percutaneously or directly across the aortic valve to unload the left ventricle. The purpose of this study is to determine the role of Impella devices in patients with acute cardiogenic shock in the perioperative period of cardiac surgery. Methods: A retrospective single-surgeon review of 11 consecutive patients who underwent placement of Impella devices in the perioperative period of cardiac surgery was performed. Patient records were evaluated for demographics, indications for placement, and postoperative outcomes. Results: Impella devices were placed for refractory cardiogenic shock preoperatively in 6 patients, intraoperatively in 4 patients, and postoperatively as a rescue in 1 patient. Seven patients received Impella CP, 1 Impella RP, 1 Impella CP and RP, and 2 Impella 5.0. Additionally, 3 patients required preoperative venovenous extracorporeal membrane oxygenation (VV-ECMO), and 1 patient required intraoperative venoarterial extracorporeal membrane oxygenation (VA-ECMO). All Impella devices were removed 1 to 28 days after implantation. Length of stay in the intensive care unit stay ranged from 2 to 53 days (average 23.9 +/- 14.6). The 30-day and 1-year mortality were 0%. Ten of 11 patients were alive at 2 years. Also, 1 patient died 18 months after surgery from complications of coronavirus disease (Covid-19). Device-related complications included varying degrees of hemolysis in 8 patients (73%) and device malfunction in 1 patient (9%). Conclusions: The Impella ventricular support system can be combined with other mechanical support devices for additional hemodynamic support. All patients demonstrated myocardial recovery with no deaths in the perioperative period and in 1-year of follow-up. Larger studies are necessary to validate these findings.
引用
收藏
页码:71 / 78
页数:8
相关论文
共 50 条
  • [41] Impella Versus Extracorporeal Membrane Oxygenation for Acute Myocardial Infarction Cardiogenic Shock
    Lemor, Alejandro
    Dehkordi, Seyed Hamed Hosseini
    Basir, Mir B.
    Villablanca, Pedro A.
    Jain, Tarun
    Koenig, Gerald C.
    Alaswad, Khaldoon
    Moses, Jeffrey W.
    Kapur, Navin K.
    O'Neill, William
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2020, 21 (12) : 1465 - 1471
  • [42] Aspirin and clopidogrel use in the perioperative period for non-cardiac surgery
    Price, Jennifer
    Tadbiri, Shahrzhad
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (01) : 56 - 56
  • [43] The Early use of Impella-Ventricular Assist Devices in Patients with acute Coronary Syndrome and cardiogenic Shock is Based on the Advantage of 1-Year Mortality
    Schroeter, M.
    Koehler, H.
    Wachter, A.
    Bleckmann, A.
    Hasenfuss, G.
    Schillinger, W.
    INTERNIST, 2016, 57 : S30 - S30
  • [44] Impella in Acute Myocardial Infarction Complicated by Cardiogenic Shock: History and Current Controversies
    Panhwar, Muhammad Siyab
    Reed, Grant W.
    Jain, Vardhmaan
    Ayoub, Ali
    Menon, Venu
    Lahorra, Joseph A.
    Kanaa'N, Anmar
    Hedrick, David P.
    Kapadia, Samir R.
    LeJemtel, Thierry
    Kalra, Ankur
    JOURNAL OF INVASIVE CARDIOLOGY, 2022, 34 (10): : E709 - E719
  • [45] Rebuttal: The Use of PTCA in Acute Mitral Regurgitation and Cardiogenic Shock: Revisited With Impella-Response from the Authors
    Boccalandro, Fernando
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 82 (03) : 425 - 425
  • [46] Impella devices: a comprehensive review of their development, use, and impact on cardiogenic shock and high-risk percutaneous coronary intervention
    Fishkin, Tzvi
    Isath, Ameesh
    Naami, Edmund
    Aronow, Wilbert S. S.
    Levine, Avi
    Gass, Alan
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2023, 21 (09) : 613 - 620
  • [48] The Current Use of Impella 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry
    O'Neill, William W.
    Dixon, Simon
    Massaro, Joseph
    Naidu, Srihari S.
    Ohman, E. Magnus
    Rihal, Charanjit
    Schreiber, Theodore
    Wohns, David H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B137 - B137
  • [49] The Current Use of Impella 2.5 in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Results from the USpella Registry
    O'Neill, William W.
    Schreiber, Theodore
    Wohns, David H. W.
    Rihal, Charanjit
    Naidu, Srihari S.
    Civitello, Andrew B.
    Dixon, Simon R.
    Massaro, Joseph M.
    Maini, Brijeshwar
    Ohman, E. Magnus
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2014, 27 (01) : 1 - 11
  • [50] PALLIATIVE MANAGEMENT AND END OF LIFE CARE WITH PROLONGED IMPELLA USE IN CARDIOGENIC SHOCK
    Falta, Sarah
    Yacono, Paul
    Rhinehart, Zachary
    Thorngren, Christina
    Kaczorowski, David
    Hickey, Gavin W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 4517 - 4517